Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Cancers, Free Full-Text

PDF) A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration

Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor

Prostate cancer - The Lancet

Clovis trots out Rubraca prostate cancer partial win

Rucaparib Improves rPFS Vs Physician's Choice in BRCA+ mCRPC

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?

Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?